Look M P, Rockstroh J K, Rao G S, Kreuzer K A, Barton S, Lemoch H, Sudhop T, Hoch J, Stockinger K, Spengler U, Sauerbruch T
Department of General Internal Medicine, University of Bonn, Germany.
Eur J Clin Nutr. 1997 Apr;51(4):266-72. doi: 10.1038/sj.ejcn.1600401.
Antioxidant defense status was investigated in HIV-infected patients by measuring serum selenium, erythrocyte glutathione peroxidase (GSH-Px) activity, plasma thiol (-SH) and glutathione (GSH) concentrations along with the assessment of the clinical stage and surrogate markers of HIV-disease.
DESIGN, SETTING AND SUBJECTS: Serum selenium levels were determined cross-sectionally in 104 sequentially selected HIV-infected patients (83 outpatients and 21 patients with ongoing AIDS defining events). The patients were classified into three stages of the disease, I, II and III according to the 1993 Centers For Disease Control (CDC) classification system for HIV-infection. GSH-Px activities, plasma SH and plasma GSH concentrations were determined in a subset of 24 patients at stage I and 12 patients at stage III with an active AIDS-defining disease.
Mean serum selenium levels were lower in CDC stage II (68.7 +/- 20.9 micrograms/l; P < 0.01; n = 34) and stage III (51.4 +/- 14.7 micrograms/l; P < 0.01; n = 37) HIV-infected patients than in healthy subjects (89.2 +/- 20.9 micrograms/l; n = 72) and stage I patients (82.3 +/- 20.5; microgram/l; n = 33). Serum selenium levels were positively correlated with CD4-count (r = 0.42; P < 0.001; n = 104) and inversely with levels of soluble tumor necrosis factor receptors type II (r = -0.58; P < 0.01; n = 35), neopterin (r = -0.5; P < 0.001; n = 80) and beta 2-microglobulin (r = -0.4; P < 0.001; n = 94). Hepatitis C virus (HCV) and HIV-coinfected patients at CDC stages I and II showed markedly lower selenium concentrations compared to HIV-infected patients without concomitant HCV-infection. Serum selenium and GSH-Px activity in hospitalized AIDS patients was significantly lower as compared to asymptomatic patients and healthy subjects, whereas plasma SH and GSH concentrations were lower in both, asymptomatic -and AIDS-patients, than in the controls.
The results show that stages I-III of HIV-disease are characterized by significant impairments of antioxidative defenses provided by selenium, GSH-Px, SH-groups and GSH.
通过检测血清硒、红细胞谷胱甘肽过氧化物酶（GSH-Px）活性、血浆硫醇（-SH）和谷胱甘肽（GSH）浓度，并评估HIV疾病的临床分期和替代标志物，对HIV感染患者的抗氧化防御状态进行研究。
设计、地点和研究对象：对104例依次入选的HIV感染患者（83例门诊患者和21例有正在发生的艾滋病界定事件的患者）进行血清硒水平的横断面测定。根据1993年美国疾病控制中心（CDC）的HIV感染分类系统，将患者分为疾病的I、II和III期。在24例I期患者和12例有活动性艾滋病界定疾病的III期患者中测定了GSH-Px活性、血浆SH和血浆GSH浓度。
与健康受试者（89.2±20.9微克/升；n = 72）和I期患者（82.3±20.5微克/升；n = 33）相比，CDC II期（68.7±20.9微克/升；P < 0.01；n = 34）和III期（51.4±14.7微克/升；P < 0.01；n = 37）HIV感染患者的平均血清硒水平较低。血清硒水平与CD4细胞计数呈正相关（r = 0.42；P < 0.001；n = 104），与可溶性肿瘤坏死因子受体II型水平呈负相关（r = -0.58；P < 0.01；n = 35）、新蝶呤（r = -0.5；P < 0.001；n = 80）和β2-微球蛋白（r = -0.4；P < 0.001；n = 94）。与未合并丙型肝炎病毒（HCV）感染的HIV感染患者相比，CDC I期和II期合并HCV和HIV感染的患者硒浓度明显较低。与无症状患者和健康受试者相比，住院艾滋病患者的血清硒和GSH-Px活性明显较低，而无症状患者和艾滋病患者的血浆SH和GSH浓度均低于对照组。
结果表明，HIV疾病的I-III期特征为硒、GSH-Px、SH基团和GSH提供的抗氧化防御功能显著受损。
